Genes are the basic units of inheritance. They are made from DNA and carry the instructions that help determine how living organisms grow, function and pass on traits. These traits can include visible features such as hair colour and height, as well as biological characteristics that are less obvious, such as blood clotting, insulin production or vulnerability to certain conditions.
For biotechnology companies, understanding how genes behave is central to developing treatments that are more targeted and better aligned with the biology of disease. Not all genes work in the same way. Some need other genes to produce an effect, some can act alone, and some combine with others to create stronger or more complex outcomes. Gene-based medicine depends on identifying the right mechanism, testing it carefully and building a clear route from scientific insight to potential therapy.
Complementary genes work together. A specific trait may only appear when two dominant genes are present at the same time. One gene on its own may not be enough. This shows why genetic research often requires precision. A treatment strategy may need to account for more than one biological factor, rather than focusing on a single gene in isolation.
Supplementary genes operate in a related but different way. One dominant gene can produce a trait by itself, while another gene only has an effect when it is paired with the first. When both are present, the result can change. This helps explain why gene activity is not always simple or predictable. The same gene may have different effects depending on the wider genetic environment.
Polymeric genes, also known as additive genes, work by combining their effects. Several genes may contribute to one trait, creating a stronger result together than any single gene would produce alone. This is relevant to complex biological processes such as ageing, where several pathways may be involved at once. It also means development work must be carefully validated, because changing one part of the system may not be enough to create a meaningful clinical effect.
Sex-linked genes are carried on the X and Y chromosomes. Because males have one X chromosome, some recessive traits carried on that chromosome are more likely to appear. Colour blindness is one example. These inheritance patterns can affect how conditions appear across populations and may influence how future genetic treatments are studied.
Mutations can change how genes function and may contribute to disease, ageing or resilience. The article highlights SIRT6, a gene linked to DNA damage repair and ageing. Genflow Biosciences has identified SIRT6 mutations in centenarians and is exploring whether a centenarian version of the gene could support DNA repair and help slow or delay aspects of ageing through gene therapy.
Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives
